Kathleen N Moore1,2, David S Hong3, Manish R Patel4,5, Shubham Pant6,3, Susanna V Ulahannan6,4, Suzanne Jones4, Funda Meric-Bernstam3, Judy S Wang4,5, Raid Aljumaily6,4, Erika P Hamilton4,7, Erika S Wittchen8, Xuejing Wang9, Aimee Bence Lin9, Johanna C Bendell4,7. 1. Stephenson Cancer Center, University of Oklahoma Health Sciences Center, 920 Stanton L Young Blvd WP2350, Oklahoma City, OK, 73104, USA. kathleen-moore@ouhsc.edu. 2. Sarah Cannon Research Institute, Nashville, TN, USA. kathleen-moore@ouhsc.edu. 3. The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. Sarah Cannon Research Institute, Nashville, TN, USA. 5. Florida Cancer Specialists and Research Institute, Sarasota, FL, USA. 6. Stephenson Cancer Center, University of Oklahoma Health Sciences Center, 920 Stanton L Young Blvd WP2350, Oklahoma City, OK, 73104, USA. 7. Tennessee Oncology, Nashville, TN, USA. 8. Syneos Health, Morrisville, NC, USA. 9. Eli Lilly and Company, Indianapolis, IN, USA.
Abstract
BACKGROUND: The checkpoint kinase 1 (CHK1) inhibitor prexasertib exhibited modest monotherapy antitumor activity in prior trials, suggesting that combination with chemotherapy or other targeted agents may be needed to maximize efficacy. OBJECTIVES: The aim of this study was to determine the recommended phase II dose and schedule of prexasertib in combination with either cisplatin, cetuximab, pemetrexed, or 5-fluorouracil in patients with advanced and/or metastatic cancer, and to summarize preliminary antitumor activity of these combinations. PATIENTS AND METHODS: This phase Ib, nonrandomized, open-label study comprised dose-escalation phase(s) with multiple sub-arms evaluating different prexasertib-drug combinations: Part A, prexasertib + cisplatin (n = 63); Part B, prexasertib + cetuximab (n = 41); Part C, prexasertib + pemetrexed (n = 3); Part D, prexasertib + 5-fluorouracil (n =8). Alternate dose schedules/regimens intended to mitigate toxicity and maximize dose exposure and efficacy were also explored in sub-parts. RESULTS: In Part A, the maximum tolerated dose (MTD) of prexasertib in combination with cisplatin (75 mg/m2) was declared at 80 mg/m2, with cisplatin administered on Day 1 and prexasertib on Day 2 of a 21-day cycle. The overall objective response rate (ORR) in Part A was 12.7%, and 28 of 55 evaluable patients (50.9%) had a decrease in target lesions from baseline. The most frequent treatment-related adverse events (AEs) in Part A were hematologic, with the most common being white blood cell count decreased/neutrophil count decreased, experienced by 73.0% (any grade) and 66.7% (grade 3 or higher) of patients. In Part B, an MTD of 70 mg/m2 was established for prexasertib administered in combination with cetuximab (500 mg /m2), both administered on Day 1 of a 14-day cycle. The overall ORR in Part B was 4.9%, and 7 of 31 evaluable patients (22.6%) had decreased target lesions compared with baseline. White blood cell count decreased/neutrophil count decreased was also the most common treatment-related AE (56.1% any grade; 53.7% grade 3 or higher). In Parts A and B, hematologic toxicities, even with the addition of prophylactic granulocyte colony-stimulating factor, resulted in frequent dose adjustments (> 60% of patients). In Part C, evaluation of prexasertib + pemetrexed was halted due to dose-limiting toxicities in two of the first three patients; MTD was not established. In Part D, the MTD of prexasertib in combination with 5-fluorouracil (label dose) was declared at 40 mg /m2, both administered on Day 1 of a 14-day cycle. In Part D, overall ORR was 12.5%. CONCLUSIONS: This study demonstrated the proof-of-concept that prexasertib can be combined with cisplatin, cetuximab, and 5-fluorouracil. Schedule was a key determinant of the tolerability and feasibility of combining prexasertib with these standard-of-care agents. Reversible hematologic toxicity was the most frequent AE and was dose-limiting. Insights gleaned from this study will inform future combination strategies for the development of prexasertib and next-generation CHK1 inhibitors. CLINICALTRIALS. GOV IDENTIFIER: NCT02124148 (date of registration 28 April 2014).
BACKGROUND: The checkpoint kinase 1 (CHK1) inhibitor prexasertib exhibited modest monotherapy antitumor activity in prior trials, suggesting that combination with chemotherapy or other targeted agents may be needed to maximize efficacy. OBJECTIVES: The aim of this study was to determine the recommended phase II dose and schedule of prexasertib in combination with either cisplatin, cetuximab, pemetrexed, or 5-fluorouracil in patients with advanced and/or metastatic cancer, and to summarize preliminary antitumor activity of these combinations. PATIENTS AND METHODS: This phase Ib, nonrandomized, open-label study comprised dose-escalation phase(s) with multiple sub-arms evaluating different prexasertib-drug combinations: Part A, prexasertib + cisplatin (n = 63); Part B, prexasertib + cetuximab (n = 41); Part C, prexasertib + pemetrexed (n = 3); Part D, prexasertib + 5-fluorouracil (n =8). Alternate dose schedules/regimens intended to mitigate toxicity and maximize dose exposure and efficacy were also explored in sub-parts. RESULTS: In Part A, the maximum tolerated dose (MTD) of prexasertib in combination with cisplatin (75 mg/m2) was declared at 80 mg/m2, with cisplatin administered on Day 1 and prexasertib on Day 2 of a 21-day cycle. The overall objective response rate (ORR) in Part A was 12.7%, and 28 of 55 evaluable patients (50.9%) had a decrease in target lesions from baseline. The most frequent treatment-related adverse events (AEs) in Part A were hematologic, with the most common being white blood cell count decreased/neutrophil count decreased, experienced by 73.0% (any grade) and 66.7% (grade 3 or higher) of patients. In Part B, an MTD of 70 mg/m2 was established for prexasertib administered in combination with cetuximab (500 mg /m2), both administered on Day 1 of a 14-day cycle. The overall ORR in Part B was 4.9%, and 7 of 31 evaluable patients (22.6%) had decreased target lesions compared with baseline. White blood cell count decreased/neutrophil count decreased was also the most common treatment-related AE (56.1% any grade; 53.7% grade 3 or higher). In Parts A and B, hematologic toxicities, even with the addition of prophylactic granulocyte colony-stimulating factor, resulted in frequent dose adjustments (> 60% of patients). In Part C, evaluation of prexasertib + pemetrexed was halted due to dose-limiting toxicities in two of the first three patients; MTD was not established. In Part D, the MTD of prexasertib in combination with 5-fluorouracil (label dose) was declared at 40 mg /m2, both administered on Day 1 of a 14-day cycle. In Part D, overall ORR was 12.5%. CONCLUSIONS: This study demonstrated the proof-of-concept that prexasertib can be combined with cisplatin, cetuximab, and 5-fluorouracil. Schedule was a key determinant of the tolerability and feasibility of combining prexasertib with these standard-of-care agents. Reversible hematologic toxicity was the most frequent AE and was dose-limiting. Insights gleaned from this study will inform future combination strategies for the development of prexasertib and next-generation CHK1 inhibitors. CLINICALTRIALS. GOV IDENTIFIER: NCT02124148 (date of registration 28 April 2014).
Authors: Shilpi Arora; Kristen M Bisanz; Lourdes A Peralta; Gargi D Basu; Ashish Choudhary; Raoul Tibes; David O Azorsa Journal: Gynecol Oncol Date: 2010-09 Impact factor: 5.482
Authors: Johanna C Bendell; Helge G Bischoff; Jimmy Hwang; Hans Christian Reinhardt; Thomas Zander; Xuejing Wang; Scott Hynes; Celine Pitou; Robert Campbell; Philip Iversen; Daphne L Farrington; Katherine Bell-McGuinn; Michael Thomas Journal: Invest New Drugs Date: 2019-11-09 Impact factor: 3.850
Authors: Constance King; H Bruce Diaz; Samuel McNeely; Darlene Barnard; Jack Dempsey; Wayne Blosser; Richard Beckmann; David Barda; Mark S Marshall Journal: Mol Cancer Ther Date: 2015-07-03 Impact factor: 6.261
Authors: Mayur A Gadhikar; Maria Rita Sciuto; Marcus Vinicius Ortega Alves; Curtis R Pickering; Abdullah A Osman; David M Neskey; Mei Zhao; Alison L Fitzgerald; Jeffrey N Myers; Mitchell J Frederick Journal: Mol Cancer Ther Date: 2013-07-09 Impact factor: 6.261
Authors: David S Hong; Kathleen Moore; Manish Patel; Stefan C Grant; Howard A Burris; William N William; Suzanne Jones; Funda Meric-Bernstam; Jeffrey Infante; Lisa Golden; Wei Zhang; Ricardo Martinez; Sameera Wijayawardana; Richard Beckmann; Aimee Bence Lin; Cathy Eng; Johanna Bendell Journal: Clin Cancer Res Date: 2018-04-11 Impact factor: 12.531
Authors: David Hong; Jeffrey Infante; Filip Janku; Suzanne Jones; Ly M Nguyen; Howard Burris; Aung Naing; Todd M Bauer; Sarina Piha-Paul; Faye M Johnson; Razelle Kurzrock; Lisa Golden; Scott Hynes; Ji Lin; Aimee Bence Lin; Johanna Bendell Journal: J Clin Oncol Date: 2016-04-04 Impact factor: 44.544
Authors: M Bartucci; S Svensson; P Romania; R Dattilo; M Patrizii; M Signore; S Navarra; F Lotti; M Biffoni; E Pilozzi; E Duranti; S Martinelli; C Rinaldo; A Zeuner; M Maugeri-Saccà; A Eramo; R De Maria Journal: Cell Death Differ Date: 2011-11-25 Impact factor: 15.828